Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study.
Eur Urol
; 84(5): 449-454, 2023 11.
Article
in En
| MEDLINE
| ID: mdl-37500340
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Carcinoma, Renal Cell
/
Kidney Neoplasms
Type of study:
Clinical_trials
Limits:
Humans
Language:
En
Journal:
Eur Urol
Year:
2023
Document type:
Article
Country of publication:
Suiza